Project Renewal: US FDA's Plan To Update Generic Cancer Drug Labels Depends On NDA Holders

Agency has targeted 40 older generic chemotherapeutics for revised labeling; FDA will develop the new labeling, which will include currently accepted uses, but needs the cooperation of reference product holders who would actually have to submit the supplement.

Bottles of pills arranged on shelf at drugstore

The US FDA is embarking on a mission to update labeling of generic chemotherapy drugs, but the initiative's success may depend upon the cooperation of reference product sponsors.

Under an initiative dubbed Project Renewal, FDA plans to modernize the labeling of approximately 40 older generic chemotherapeutics, according to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

Philippines Seeks Feedback On Plan To Recognize BE Studies Under ASEAN Deal

The Philippines medicines regulator explains how it intends to implement the ASEAN mutual recognition agreement under which member states have committed to accept bioequivalence study reports for generics issued by approved BE centers.

Finance Watch: Many Mega-Rounds, Some Smaller VC Deals, But Few In The Middle-Test-Sabbah

 
• By 

Private Company Edition: June’s eight $100m-plus venture capital rounds already outpace the seven each raised in March, April and May, including €255m ($274.2m) for ITM and $200m for Upstream, but while there were five $25m or less VC financings during the past week, mid-sized deals were lacking.

Novartis Takes Fight To The FDA After US Entresto Generic Approval

 
• By 

Novartis continues to fight tooth and nail to protect its $3bn Entresto brand in the US following the latest FDA approval of a generic version.

Covid

More from Biosimilars & Generics

Facility Deficiencies Drive Rising CRL Rates For CDER Biologics

 

A US FDA analysis found that facility inspection issues were the fastest growing factor in the recent rise of complete response letters for biologics licensing applications, in part reflecting the limitations of single-product inspections at contract facilities manufacturing multiple products.

Novartis Takes Fight To The FDA After US Entresto Generic Approval

 
• By 

Novartis continues to fight tooth and nail to protect its $3bn Entresto brand in the US following the latest FDA approval of a generic version.

EU Biosimilar Filings, Opinions And Approvals

 
• By 

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.